Hypertrophic cardiomyopathy: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SGLT2 2
• GLP-1 0
• MEK 2
• MAPK 0
• PI3K 0
• STAT3 0
• TTR 0
• AKT 0
• CTNNB1 0
• ERK 0
• IL-6 0
• KRAS 0
• mTOR 0
• NRF2 0
• PSEN1 0
• SHP2 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 836 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Viz.ai, Inc.· Updated 23 Sept 2026

  “Sponsor company opted to shift design into single center investigator initiated study focus.”Registry text, quoted unchanged. Source

• Terminated

  A Cardiac Disease Quality of Life Study

  NCT04080492· The Cleveland Clinic· Updated 17 Sept 2026

  “Enrollment goal not met”Registry text, quoted unchanged. Source

• Terminated

  ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

  NCT07155434· UltraSight· Updated 9 Mar 2026

  “The sponsor terminated the study following an internal review of program priorities.”Registry text, quoted unchanged. Source

• Terminated

  Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

  NCT06775886· Montefiore Medical Center· Updated 11 Feb 2026

  “PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.”Registry text, quoted unchanged. Source

• Terminated

  NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Updated 18 Dec 2025

  “Clinical trials terminated early due to trial feasibility”Registry text, quoted unchanged. Source

• Withdrawn

  OPIE in the Thin Interventricular Septum

  NCT04050579· NYU Langone Health· Updated 11 Jun 2025

  “Study was determined to be focused on Quality Assurance (QA) and Quality Improvement (QI), rather than research, based on its primary purpose and activities. Study was closed prior to enrollment.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Individualized Exercise Training in Hypertrophic Cardiomyopathy

  NCT07835854· Oregon Health and Science University· Source

• A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06112743· Bristol-Myers Squibb· Source

• Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions

  NCT07131371· Tampere University· Source

• Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Cytokinetics· Source

• A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

  NCT07004972· Bristol-Myers Squibb· Source

• Perfusion Abnormalities in Hypertrophic Cardiomyopathy

  NCT06599229· University of Virginia· Source

• A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

  NCT03723655· Bristol-Myers Squibb· Source

• A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

  NCT06253221· Bristol-Myers Squibb· Source

• NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

  NCT06269640· National Heart, Lung, and Blood Institute (NHLBI)· Source

• Transapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

  NCT05648825· Xiang Wei· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 17
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 8
• Proteomics 6
• Metabolomics 2
• Immunohistochemistry 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 39
• Machine Learning 13
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 9

• AI-assisted diagnosis of cardiac amyloidosis using electrocardiograms and echocardiography: a multicenter retrospective study in China.

  BMC Med, Jun 2026

• Integrative Transcriptomics and Machine Learning Identify Macrophage-Associated Biomarkers in Hypertrophic Cardiomyopathy.

  Int J Mol Sci, Jun 2026

• Machine Learning-based Model for Major Adverse Cardiac Event Prediction in Patients with Hypertrophic Cardiomyopathy.

  Radiol Cardiothorac Imaging, Jun 2026

• Machine learning-based risk stratification identifies heart failure with preserved ejection fraction as an independent predictor of adverse outcomes in hypertrophic cardiomyopathy.

  Sci Rep, Apr 2026

• Application of untargeted plasma metabolomics and machine learning to construct a diagnostic model for hypertrophic cardiomyopathy: a case-control study.

  Metabolomics, Mar 2026

• Non-contrast multimodal cardiac MRI for predicting coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy.

  Magn Reson Imaging, Mar 2026

• ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform.

  Brief Bioinform, Mar 2026

• Identification of Cuproptosis-Associated Biomarker Candidates in Hypertrophic Cardiomyopathy via Machine Learning and Multi-Omics Integration.

  Appl Biochem Biotechnol, Jan 2026

• Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence.

  Curr Probl Cardiol, Dec 2025

• A machine Learning-Based risk stratification using CMR volumetric and strain parameters in patients with hypertrophic cardiomyopathy.

  Int J Cardiovasc Imaging, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.